In "New Shares," Zhonghui Biological's public offering was oversubscribed by nearly 4,007 times, with a one-hand winning rate of 10%

AB&B BIO-TECH-B (02627.HK) announced the results of its IPO, with the Hong Kong public offering receiving 4,007.64 times subscription, and the winning rate for one board lot (200 shares) is 10%. A subscription of 900,000 shares is required to secure one board lot. The international offering recorded 0.99 times subscription. After reallocation, the number of shares available for public offering has increased to 3.996 million shares, accounting for 11.95% of the total offering. The final offer price is HKD 12.9, which is the lower limit of the price range, raising a net amount of approximately HKD 383 million. The shares are expected to be listed on Monday (11th).

The vaccine company Jiangsu Zhonghui Yuantong Biotechnology plans to globally offer 33.4426 million H shares, with the public offering originally accounting for 10%. The offer price ranges from HKD 12.9 to HKD 15.5. Cornerstone investor Jiaxing Xinyang subscribed for 7.83 million shares